

May 11, 2016
 SymBio Pharmaceuticals Limited
 Fuminori Yoshida
 Representative Director
 President and Chief Executive Officer
 (Securities Code: 4582)

SymBio Announces Incorporation of its U.S. Subsidiary

TOKYO, Japan, May 11, 2016 --- SymBio Pharmaceuticals Limited (Headquarters: Tokyo, “the Company”) announced today that the Company has incorporated its wholly-owned subsidiary in the United States - SymBio Pharma USA, Inc. (Headquarters: Menlo Park, California, USA, President: Mr. Fuminori Yoshida).

SymBio Pharma USA, Inc. was established to serve as a foothold to accelerate the transformation of SymBio Pharmaceuticals Limited based in Tokyo, Japan into a global specialty pharmaceutical company by acquiring worldwide rights to new drug candidates, platform technologies and devices, and developing and commercializing them in major markets including the U.S., Japan and Europe.

Mr. Yoshida, President and Chief Executive Officer said, “SymBio Pharma USA will be uniquely situated in Silicon Valley where innovation in life science and communication technology that will evolve into new medicines based on eHealth is taking place. Also, equally importantly, the ecosystem crucial to fostering growth and expansion of biotech business is well established in the area. The establishment of SymBio Pharma USA will enable the Company to gain greater access to advanced research institutes such as Stanford University, and communication technology and biotech companies throughout the U.S.”

SymBio Pharma USA, Inc. (summary)

Name	SymBio Pharma USA, Inc.
Address	Menlo Park, California, USA
President	Fuminori Yoshida
Establishment Date	May 10, 2016 - Pacific Standard Time May 11, 2016 - Japan Standard Time
Shareholders	A 100% Subsidiary of SymBio Pharmaceuticals Limited
Business Activities	Research and Development, Manufacturing and Sales of Pharmaceutical Products

This event will not impact the Company's current financial forecast.

[Contact]

Investor Relations

Tel: +81 (0)3 5472 1125

About SymBio Pharmaceuticals Limited

SymBio Pharmaceuticals Limited was established in March, 2005, by Fuminori Yoshida who previously served concurrently as Corporate VP of Amgen Inc. and founding President of Amgen Japan. The Company's underlying corporate mission is to "deliver hope to patients in need" as it aspires to be a leading global specialty pharmaceutical company dedicated to addressing underserved medical needs with main therapeutic focus in oncology, hematology and pain management.